A Polymorphism at the microRNA Binding Site in the 3' Untranslated Region of KRT81 Is Associated with Breast Cancer

DNA and Cell Biology
Ziyue ShaZhanjun Guo

Abstract

Single nucleotide polymorphisms in miRNA binding sites (miR-SNPs) are associated with cancer risk. We assessed the relationship between five miR-SNPs in the 3' untranslated region (3'-UTR) of RYR3 (rs1044129), KIAA0423 (rs1053667), C14orf101 (rs4901706), GOLGA7 (rs11337), and KRT81 (rs3660) and the risk of breast cancer (BC). The CC genotype of rs3660 located in the 3'-UTR of KRT81 was identified for its association with lower BC risk (odds ratio, 0.093; 95% confidence interval, 0.045-0.193; p = 0.000). Immunnochemical analysis and Renilla luciferase reporter assays indicated that the CC genotype of KRT81 was associated with lower expression of KRT81 (p < 0.05). The subsequently functional analysis showed that knockdown the KRT81 could inhibit proliferation and promote apoptosis of the MDA-MB-231 BC cells (p < 0.05) with monocyte chemotactic protein-1 (MCP-1) deregulation. Meanwhile, KRT81 overexpression could promote the proliferation and inhibit the apoptosis of MCF-7 BC cells (p < 0.05). Our data demonstrated that the KRT81 expressional change modulated by rs3660 miR-SNP could modify the carcinogenesis of BC, thereby KRT81 would be a new target for BC treatment.

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F VizosoC López-Otín
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Jan 17, 2002·Current Opinion in Cell Biology·Pierre A Coulombe, M Bishr Omary
Jan 11, 2003·Clinical and Diagnostic Laboratory Immunology·Wilco de JagerGer T Rijkers
May 4, 2004·Methods : a Companion to Methods in Enzymology·Brian DalbyValentina C Ciccarone
Apr 17, 2007·Experimental Cell Research·Thomas M MaginRudolf E Leube
Feb 9, 2008·The Journal of Clinical Investigation·Guowu HuPeter R Williamson
May 8, 2008·Histochemistry and Cell Biology·Roland MollLutz Langbein
Nov 22, 2008·Biochemical Society Transactions·Ian G CannellMartin Bushell
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yohei HorikawaXifeng Wu
Dec 14, 2011·Breast Cancer Research and Treatment·Siying WangJia Luo
Apr 28, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carlos Fernández de LarreaJoan Bladé
Jul 10, 2012·Molecular Aspects of Medicine·Marcos Malumbres
Aug 21, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Che YanhuaHutcha Sriplung
May 30, 2014·The Lancet Oncology·Lei FanPaul E Goss
Feb 27, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Y LeeJ Y Park
Nov 13, 2019·Current Osteoporosis Reports·Bridie S MulhollandNigel A Morrison
Dec 22, 2019·Cells·Xueqiao JiaoLixia Xiong
Jun 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Y LeeJ Y Park

❮ Previous
Next ❯

Citations

Oct 2, 2021·Archives of Toxicology·Yuhui YuMinjie Chu

❮ Previous
Next ❯

Datasets Mentioned

BETA
KIAA0423

Methods Mentioned

BETA
PCR
Genotyping
transfection
Assay
flow cytometry
flow fluorescence

Software Mentioned

Statistical Package for the Social Sciences
SPSS

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis